Sign up online today & collaborate
or click here to find out more
Novartis is evaluating a potential regulatory filing for Arzerra in relapsed chronic lymphocytic leukaemia after the drug was shown to significantly increase progression-free survival in a Phase III trial.
Data from the COMPLEMENT 2 study show that a combination of Arzerra (ofatumumab), fludarabine and cyclophosphamide boosted progression-free survival by 54% compared to therapy with the latter two drugs alone (28.9 months versus 18.8 months, respectively).For more click here
Source: Pharma Times